Vitrolife - Public Comps and Valuation Multiples

Vitrolife Overview

About Vitrolife

Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient’s fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.

Founded

1994

HQ

Employees

1.1K+

Website

vitrolife.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $367M

LTM EBITDA $114M

EV

$2.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Vitrolife Financials

As of September 2025, Vitrolife reported last 12-month revenue of $367M and EBITDA of $114M.

In the same period, Vitrolife generated $215M in LTM gross profit and $47.2M in net income.

See Vitrolife valuation multiples based on analyst estimates

Vitrolife P&L

In the most recent fiscal year, Vitrolife reported revenue of $380M and EBITDA of $128M.

Vitrolife expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Vitrolife valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$367M	XXX	$380M	XXX	XXX	XXX
Gross Profit	$215M	XXX	$225M	XXX	XXX	XXX
Gross Margin	59%	XXX	59%	XXX	XXX	XXX
EBITDA	$114M	XXX	$128M	XXX	XXX	XXX
EBITDA Margin	31%	XXX	34%	XXX	XXX	XXX
EBIT	$74.2M	XXX	$83.2M	XXX	XXX	XXX
EBIT Margin	20%	XXX	22%	XXX	XXX	XXX
Net Profit	$47.2M	XXX	$54.0M	XXX	XXX	XXX
Net Margin	13%	XXX	14%	XXX	XXX	XXX
Net Debt	XXX	XXX	$85.9M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Vitrolife including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $367M. EBITDA for the last twelve months was $114M. In the most recent fiscal year, Vitrolife achieved $380M in revenue and $128M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$367M	Analyst estimates available to subscribers	$380M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$215M	Analyst estimates available to subscribers	$225M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	58.5% gross margin	Analyst estimates available to subscribers	59.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$114M	Analyst estimates available to subscribers	$128M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	31.0% EBITDA margin	Analyst estimates available to subscribers	33.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$74.2M	Analyst estimates available to subscribers	$83.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	20.2% EBIT margin	Analyst estimates available to subscribers	21.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$47.2M	Analyst estimates available to subscribers	$54.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.9% net profit margin	Analyst estimates available to subscribers	14.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$85.9M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Vitrolife

This financial data table provides comprehensive performance metrics for Vitrolife, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Vitrolife generated $367M in revenue over the last twelve months.
The company achieved $114M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $215M.
Net income over the last twelve months reached $47.2M.

Fiscal Year Performance

In the most recent fiscal year, Vitrolife reported $380M in total revenue.
Fiscal year EBITDA was $128M.
The company maintained a gross profit margin of 59.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.6%.
Net profit margin reached 14.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Vitrolife. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Vitrolife Stock Performance

Vitrolife has current market cap of SEK 19.8B (or $2.1B), and EV of SEK 20.8B (or $2.2B).

Market Cap Evolution

Vitrolife Stock Data

As of October 17, 2025, Vitrolife's stock price is SEK 146 (or $15).

See Vitrolife trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.2B	$2.1B	XXX	XXX	XXX	XXX	$0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Vitrolife Valuation Multiples

Vitrolife's trades at 5.8x EV/Revenue multiple, and 17.2x EV/EBITDA.

See valuation multiples for Vitrolife and 15K+ public comps

Vitrolife Financial Valuation Multiples

As of October 17, 2025, Vitrolife has market cap of $2.1B and EV of $2.2B.

Equity research analysts estimate Vitrolife's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vitrolife has a P/E ratio of 44.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV (current)	$2.2B	XXX	$2.2B	XXX	XXX	XXX
EV/Revenue	6.0x	XXX	5.8x	XXX	XXX	XXX
EV/EBITDA	19.3x	XXX	17.2x	XXX	XXX	XXX
EV/EBIT	29.5x	XXX	26.4x	XXX	XXX	XXX
EV/Gross Profit	10.2x	XXX	n/a	XXX	XXX	XXX
P/E	44.1x	XXX	38.5x	XXX	XXX	XXX
EV/FCF	36.2x	XXX	29.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vitrolife Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Vitrolife Margins & Growth Rates

Vitrolife's last 12 month revenue growth is 4%

Vitrolife's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Vitrolife's rule of 40 is -87% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vitrolife's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Vitrolife and other 15K+ public comps

Vitrolife Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	4%	XXX	1%	XXX	XXX	XXX
EBITDA Margin	31%	XXX	34%	XXX	XXX	XXX
EBITDA Growth	8%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-87%	XXX	38%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	41%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	21%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	37%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial